An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
Abstract Female BRCA1/BRCA2 mutation carriers are at substantially increased risk for developing breast and/or ovarian cancer, and are offered enhanced surveillance including screening from a young age and risk-reducing surgery (RRS)—mastectomy (RRM) and/or salpingo-oophorectomy (RRSO). While there are established guidelines for early detection of breast cancer in high-risk women who have not undergone RRM, there are less developed guidelines after RRM. We evaluated the schemes offered before and after RRS in internationally diverse high-risk clinics. An e-mailed survey was distributed to high-risk clinics affiliated with CIMBA. Overall, 22 centers from 16 countries responded. Pre RRS surveillance schemes overwhelmingly included breast imaging (primarily MRI) from 18 to 30 years and clinical breast exam (CBE) at 6–12 month intervals. For ovarian cancer, all but 6 centers offered semiannual/annual gynecological exam, transvaginal ultrasound, and CA 125 measurements. Post RRM, most centers offered only annual CBE while 4 centers offered annual MRI, primarily for substantial residual breast tissue. After RRSO only 4 centers offered specific gynecological surveillance. Existing guidelines for breast/ovarian cancer detection in BRCA carriers are being applied pre RRS but are not globally harmonized, and most centers offer no specific surveillance post RRS. From this comprehensive multinational study it is clear that evidence-based, long-term prospective data on the most effective scheme for BRCA carriers post RRS is needed..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:157 |
|---|---|
| Enthalten in: |
Breast cancer research and treatment - 157(2016), 2 vom: 27. Apr., Seite 319-327 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Madorsky-Feldman, Dana [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
/ |
| Anmerkungen: |
© Springer Science+Business Media New York 2016 |
|---|
| doi: |
10.1007/s10549-016-3805-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC204599645X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC204599645X | ||
| 003 | DE-627 | ||
| 005 | 20230503010138.0 | ||
| 007 | tu | ||
| 008 | 200819s2016 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10549-016-3805-0 |2 doi | |
| 035 | |a (DE-627)OLC204599645X | ||
| 035 | |a (DE-He213)s10549-016-3805-0-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Madorsky-Feldman, Dana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media New York 2016 | ||
| 520 | |a Abstract Female BRCA1/BRCA2 mutation carriers are at substantially increased risk for developing breast and/or ovarian cancer, and are offered enhanced surveillance including screening from a young age and risk-reducing surgery (RRS)—mastectomy (RRM) and/or salpingo-oophorectomy (RRSO). While there are established guidelines for early detection of breast cancer in high-risk women who have not undergone RRM, there are less developed guidelines after RRM. We evaluated the schemes offered before and after RRS in internationally diverse high-risk clinics. An e-mailed survey was distributed to high-risk clinics affiliated with CIMBA. Overall, 22 centers from 16 countries responded. Pre RRS surveillance schemes overwhelmingly included breast imaging (primarily MRI) from 18 to 30 years and clinical breast exam (CBE) at 6–12 month intervals. For ovarian cancer, all but 6 centers offered semiannual/annual gynecological exam, transvaginal ultrasound, and CA 125 measurements. Post RRM, most centers offered only annual CBE while 4 centers offered annual MRI, primarily for substantial residual breast tissue. After RRSO only 4 centers offered specific gynecological surveillance. Existing guidelines for breast/ovarian cancer detection in BRCA carriers are being applied pre RRS but are not globally harmonized, and most centers offer no specific surveillance post RRS. From this comprehensive multinational study it is clear that evidence-based, long-term prospective data on the most effective scheme for BRCA carriers post RRS is needed. | ||
| 650 | 4 | |a / | |
| 650 | 4 | |a mutation carriers | |
| 650 | 4 | |a High-risk women | |
| 650 | 4 | |a Early detection | |
| 650 | 4 | |a Risk-reducing surgery | |
| 650 | 4 | |a Surveillance schemes | |
| 700 | 1 | |a Sklair-Levy, Miri |4 aut | |
| 700 | 1 | |a Perri, Tamar |4 aut | |
| 700 | 1 | |a Laitman, Yael |4 aut | |
| 700 | 1 | |a Paluch-Shimon, Shani |4 aut | |
| 700 | 1 | |a Schmutzler, Rita |4 aut | |
| 700 | 1 | |a Rhiem, Kerstin |4 aut | |
| 700 | 1 | |a Lester, Jenny |4 aut | |
| 700 | 1 | |a Karlan, Beth Y. |4 aut | |
| 700 | 1 | |a Singer, Christian F. |4 aut | |
| 700 | 1 | |a Van Maerken, Tom |4 aut | |
| 700 | 1 | |a Claes, Kathleen |4 aut | |
| 700 | 1 | |a Brunet, Joan |4 aut | |
| 700 | 1 | |a Izquierdo, Angel |4 aut | |
| 700 | 1 | |a Teulé, Alex |4 aut | |
| 700 | 1 | |a Lee, Jong Won |4 aut | |
| 700 | 1 | |a Kim, Sung-Won |4 aut | |
| 700 | 1 | |a Arun, Banu |4 aut | |
| 700 | 1 | |a Jakubowska, Anna |4 aut | |
| 700 | 1 | |a Lubinski, Jan |4 aut | |
| 700 | 1 | |a Tucker, Katherine |4 aut | |
| 700 | 1 | |a Poplawski, Nicola K. |4 aut | |
| 700 | 1 | |a Varesco, Liliana |4 aut | |
| 700 | 1 | |a Bonelli, Luigina Ada |4 aut | |
| 700 | 1 | |a Buys, Saundra S. |4 aut | |
| 700 | 1 | |a Mitchell, Gillian |4 aut | |
| 700 | 1 | |a Tischkowitz, Marc |4 aut | |
| 700 | 1 | |a Gerdes, Anne-Marie |4 aut | |
| 700 | 1 | |a Seynaeve, Caroline |4 aut | |
| 700 | 1 | |a Robson, Mark |4 aut | |
| 700 | 1 | |a Kwong, Ava |4 aut | |
| 700 | 1 | |a Tung, Nadine |4 aut | |
| 700 | 1 | |a Tessa, Nalven |4 aut | |
| 700 | 1 | |a Domchek, Susan M. |4 aut | |
| 700 | 1 | |a Godwin, Andrew K. |4 aut | |
| 700 | 1 | |a Rantala, Johanna |4 aut | |
| 700 | 1 | |a Arver, Brita |4 aut | |
| 700 | 1 | |a Friedman, Eitan |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d Springer US, 1981 |g 157(2016), 2 vom: 27. Apr., Seite 319-327 |w (DE-627)167913557 |w (DE-600)604563-7 |w (DE-576)01590217X |x 0167-6806 |7 nnns |
| 773 | 1 | 8 | |g volume:157 |g year:2016 |g number:2 |g day:27 |g month:04 |g pages:319-327 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10549-016-3805-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 157 |j 2016 |e 2 |b 27 |c 04 |h 319-327 | ||